NTII - Miscellaneous Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : NTII - Miscellaneous

NTII 0.0001000

0.0%

Mar 7 3:00 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

From: John McCarthy	1/5/2005 9:03:58 PM
	of 1296

2005 - New Trial Memantine and MRI Assessment Summary: Functional MRI Assessment of Hippocampal Response to Treatment with Memantine The Memory Disorders Unit at Brigham and Women’s Hospital is conducting a research study for patients with mild to moderate Alzheimer’s disease (AD). The purpose of the study is to evaluate the effects of the newly FDA approved drug called memantine on memory using functional MRI (fMRI). This study design is to test Memantine against placebo (which contains no active medication) for 12 weeks, followed by 12 weeks of open label (where everyone receives Memantine). Eligible subjects must be 50 years of age and older, have a diagnosis of mild to moderate Alzheimer’s Disease with an MMSE score of 16 to 24. Subjects are asked to come to the clinic for 9 visits over 24 weeks. Subjects will undergo 4 functional MRI scans over the 24 week study, in addition to memory tests and standard AD assessment measures. All participants must have a reliable caregiver who is able to provide information about the subject’s condition and to monitor compliance to study medication. Study participants will be reimbursed for parking or transportation costs and paid $50 for completion of each fMRI scan. Partners physicians who have patients who might be interested in participating in the study should contact Dr. Dorene Rentz (e-mail drentz@partners.org), or Sara Talcott, MA (stalcott@partners.org) at Brigham and Women’s Hospital or call the Memory Disorders Unit Clinical Research Group at (617) 732-8085 All information is kept completely confidential. Contact: Sara Talcott MA Brigham and Womens Hospital 75 Francis Street Boston, MA 02115 Telephone: 617-732-8085 Email: stalcott@partners.org centerwatch.com

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next